New stock news | Hui Lun Pharmaceutical submits application to the Hong Kong Stock Exchange Main Board

According to the disclosure of Hong Kong Stock Exchange on April 2, Shanghai Huirun Pharmaceutical Co., Ltd. (referred to as Huirun Pharmaceutical) has submitted an application to list on the main board of the Hong Kong Stock Exchange, with CITIC SEC as the exclusive sponsor. The prospectus shows that Huirun Pharmaceutical is a pharmaceutical company with a good track record in drug development and commercialization. After years of continuous efforts, the company has established a comprehensive drug industry chain operation system covering research and development, production, and commercialization. Based on this foundation, the company is actively expanding its capabilities, with a focus on innovative drugs for major diseases and critical illnesses. The company already has a product portfolio consisting of over ten marketed products and multiple candidate drugs, covering key treatment areas such as immunoinflammation, pain management, oncology, and other chronic diseases. During the historical performance period, the company's revenue mainly came from the sales of its main marketed products, namely Huiweina (the only domestically approved generic levocarnitine hydrochloride in China) and Zuoyu (the first domestically produced Class II levofolinic acid in China). At the same time, the company's pipeline of innovative drugs has been steadily advancing, with four Class I innovative drugs and three Class II improved new drugs currently in clinical development.